For over 10 million Americans, osteoporosis presents a chronic, degenerative, and complex problem, with few current therapeutic options to promote bone growth. A team of researchers from Loma Linda University and the Jerry L. Pettis Memorial VA Medical Center in California have reversed the bone-degrading disease of osteoporosis in an animal model using hematopoietic stem cells [HSCs]. The research offers yet another development in our current understanding and capability for practical application in the stem cell field. Now, after having identified specific growth factors related to bone growth and proliferation, stem cell therapy is thought to holds great promise in reversing bone weakness and ultimately, morbidity and mortality.
Building on prior research with genetically modified hematopoietic stem cells (HSCs), researchers sought to identify the growth factor that caused a 45% increase in mouse bone strength. In the study, the HSCs were engineered to overexpress the growth hormone PGDFB, which led to increases in bone volume, density and connectivity density. (Note: the FDA has approved PGDFB for treating bone defects in the jaw and mouth.) The evidence, reported in the Proceedings of the National Academy of Sciences, shows a role for PGDFB in bone-growth-promoting angiogenesis and bone-marrow MSC formation.
Results from the animal models revealed rapid changes that lead to bone formation and increasing bone strength, supporting the thesis that the research offers a potentially viable pathway to treat osteoporosis in humans. To learn more about preserving your own valuable stem cells for use in future regenerative therapies visit StemSave or call 877-StemSave today.
To view the full article, click here.
The Future of Regenerative Medicine is Now™.